Innate Pharma (France) Probability of Future Stock Price Finishing Over 4.03
| IPH Stock | EUR 1.42 0.02 1.39% |
Innate |
Innate Pharma Target Price Odds to finish over 4.03
The tendency of Innate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over € 4.03 or more in 90 days |
| 1.42 | 90 days | 4.03 | near 1 |
Based on a normal probability distribution, the odds of Innate Pharma to move over € 4.03 or more in 90 days from now is near 1 (This Innate Pharma probability density function shows the probability of Innate Stock to fall within a particular range of prices over 90 days) . Probability of Innate Pharma price to stay between its current price of € 1.42 and € 4.03 at the end of the 90-day period is roughly 96.0 .
Assuming the 90 days trading horizon Innate Pharma has a beta of -0.33. This usually indicates as returns on the benchmark increase, returns on holding Innate Pharma are expected to decrease at a much lower rate. During a bear market, however, Innate Pharma is likely to outperform the market. Additionally Innate Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Innate Pharma Price Density |
| Price |
Predictive Modules for Innate Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Innate Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Innate Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Innate Pharma is not an exception. The market had few large corrections towards the Innate Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Innate Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Innate Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.52 | |
β | Beta against Dow Jones | -0.33 | |
σ | Overall volatility | 0.23 | |
Ir | Information ratio | -0.28 |
Innate Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innate Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innate Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| The company reported the revenue of 12.11 M. Net Loss for the year was (52.81 M) with loss before overhead, payroll, taxes, and interest of (22.3 M). | |
| Innate Pharma has accumulated about 103.76 M in cash with (58.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders |
Innate Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innate Stock often depends not only on the future outlook of the current and potential Innate Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innate Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.9 M | |
| Cash And Short Term Investments | 119.8 M |
Innate Pharma Technical Analysis
Innate Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Innate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innate Pharma. In general, you should focus on analyzing Innate Stock price patterns and their correlations with different microeconomic environments and drivers.
Innate Pharma Predictive Forecast Models
Innate Pharma's time-series forecasting models is one of many Innate Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Innate Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Innate Pharma
Checking the ongoing alerts about Innate Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Innate Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| The company reported the revenue of 12.11 M. Net Loss for the year was (52.81 M) with loss before overhead, payroll, taxes, and interest of (22.3 M). | |
| Innate Pharma has accumulated about 103.76 M in cash with (58.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders |
Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Innate Pharma Backtesting, Innate Pharma Valuation, Innate Pharma Correlation, Innate Pharma Hype Analysis, Innate Pharma Volatility, Innate Pharma History as well as Innate Pharma Performance. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.